Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome: The National Heart, Lung and Blood Institute Family Heart Study

Lana Y.H. Lai, Andrew B. Petrone, James S. Pankow, Donna K. Arnett, Kari E. North, R. Curtis Ellison, Steven Hunt, James L. Rosenzweig, Luc Djoussé

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Objective: Metabolic syndrome (MetS), characterized by abdominal obesity, atherogenic dyslipidaemia, elevated blood pressure and insulin resistance, is a major public health concern in the United States. The effects of apolipoprotein E (Apo E) polymorphism on MetS are not well established. Methods: We conducted a cross-sectional study consisting of 1551 participants from the National Heart, Lung and Blood Institute Family Heart Study to assess the relation of Apo E polymorphism with the prevalence of MetS. MetS was defined according to the American Heart Association-National Heart, Lung and Blood Institute-International Diabetes Federation-World Health Organization harmonized criteria. We used generalized estimating equations to estimate adjusted odds ratios (ORs) for prevalent MetS and the Bonferroni correction to account for multiple testing in the secondary analysis. Results: Our study population had a mean age (standard deviation) of 56.5 (11.0) years, and 49.7% had MetS. There was no association between the Apo E genotypes and the MetS. The multivariable adjusted ORs (95% confidence interval) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62-1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the E{open}3/E{open}3, E{open}2/E{open}2, E{open}2/E{open}3, E{open}2/E{open}4, E{open}3/E{open}4 and E{open}4/E{open}4 genotypes, respectively. In a secondary analysis, E{open}2/E{open}3 genotype was associated with 41% lower prevalence odds of low high-density lipoprotein [multivariable adjusted ORs (95% confidence interval)=0.59 (0.36-0.95)] compared with E{open}3/E{open}3 genotype. Conclusions: Our findings do not support an association between Apo E polymorphism and MetS in a multicentre population-based study of predominantly White US men and women.

Original languageEnglish
Pages (from-to)582-587
Number of pages6
JournalDiabetes/Metabolism Research and Reviews
Volume31
Issue number6
DOIs
Publication statusPublished - 1 Sep 2015
Externally publishedYes

Fingerprint

National Heart, Lung, and Blood Institute (U.S.)
Apolipoproteins E
Genotype
Odds Ratio
Confidence Intervals
HDL Lipoproteins
Dyslipidemias
LDL Lipoproteins
Population
Insulin Resistance
Public Health
Cross-Sectional Studies
Blood Pressure

Keywords

  • Apolipoprotein E (Apo E) polymorphism
  • Blood pressure
  • Dyslipidaemia
  • Glucose
  • High-density lipoprotein cholesterol
  • Metabolic syndrome

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome : The National Heart, Lung and Blood Institute Family Heart Study. / Lai, Lana Y.H.; Petrone, Andrew B.; Pankow, James S.; Arnett, Donna K.; North, Kari E.; Ellison, R. Curtis; Hunt, Steven; Rosenzweig, James L.; Djoussé, Luc.

In: Diabetes/Metabolism Research and Reviews, Vol. 31, No. 6, 01.09.2015, p. 582-587.

Research output: Contribution to journalArticle

Lai, Lana Y.H. ; Petrone, Andrew B. ; Pankow, James S. ; Arnett, Donna K. ; North, Kari E. ; Ellison, R. Curtis ; Hunt, Steven ; Rosenzweig, James L. ; Djoussé, Luc. / Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome : The National Heart, Lung and Blood Institute Family Heart Study. In: Diabetes/Metabolism Research and Reviews. 2015 ; Vol. 31, No. 6. pp. 582-587.
@article{52336aec68074d66a36a24c950fc1d96,
title = "Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome: The National Heart, Lung and Blood Institute Family Heart Study",
abstract = "Objective: Metabolic syndrome (MetS), characterized by abdominal obesity, atherogenic dyslipidaemia, elevated blood pressure and insulin resistance, is a major public health concern in the United States. The effects of apolipoprotein E (Apo E) polymorphism on MetS are not well established. Methods: We conducted a cross-sectional study consisting of 1551 participants from the National Heart, Lung and Blood Institute Family Heart Study to assess the relation of Apo E polymorphism with the prevalence of MetS. MetS was defined according to the American Heart Association-National Heart, Lung and Blood Institute-International Diabetes Federation-World Health Organization harmonized criteria. We used generalized estimating equations to estimate adjusted odds ratios (ORs) for prevalent MetS and the Bonferroni correction to account for multiple testing in the secondary analysis. Results: Our study population had a mean age (standard deviation) of 56.5 (11.0) years, and 49.7{\%} had MetS. There was no association between the Apo E genotypes and the MetS. The multivariable adjusted ORs (95{\%} confidence interval) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62-1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the E{open}3/E{open}3, E{open}2/E{open}2, E{open}2/E{open}3, E{open}2/E{open}4, E{open}3/E{open}4 and E{open}4/E{open}4 genotypes, respectively. In a secondary analysis, E{open}2/E{open}3 genotype was associated with 41{\%} lower prevalence odds of low high-density lipoprotein [multivariable adjusted ORs (95{\%} confidence interval)=0.59 (0.36-0.95)] compared with E{open}3/E{open}3 genotype. Conclusions: Our findings do not support an association between Apo E polymorphism and MetS in a multicentre population-based study of predominantly White US men and women.",
keywords = "Apolipoprotein E (Apo E) polymorphism, Blood pressure, Dyslipidaemia, Glucose, High-density lipoprotein cholesterol, Metabolic syndrome",
author = "Lai, {Lana Y.H.} and Petrone, {Andrew B.} and Pankow, {James S.} and Arnett, {Donna K.} and North, {Kari E.} and Ellison, {R. Curtis} and Steven Hunt and Rosenzweig, {James L.} and Luc Djouss{\'e}",
year = "2015",
month = "9",
day = "1",
doi = "10.1002/dmrr.2638",
language = "English",
volume = "31",
pages = "582--587",
journal = "Diabetes/Metabolism Research and Reviews",
issn = "1520-7552",
publisher = "John Wiley and Sons Ltd",
number = "6",

}

TY - JOUR

T1 - Lack of association of apolipoprotein E (Apo E) polymorphism with the prevalence of metabolic syndrome

T2 - The National Heart, Lung and Blood Institute Family Heart Study

AU - Lai, Lana Y.H.

AU - Petrone, Andrew B.

AU - Pankow, James S.

AU - Arnett, Donna K.

AU - North, Kari E.

AU - Ellison, R. Curtis

AU - Hunt, Steven

AU - Rosenzweig, James L.

AU - Djoussé, Luc

PY - 2015/9/1

Y1 - 2015/9/1

N2 - Objective: Metabolic syndrome (MetS), characterized by abdominal obesity, atherogenic dyslipidaemia, elevated blood pressure and insulin resistance, is a major public health concern in the United States. The effects of apolipoprotein E (Apo E) polymorphism on MetS are not well established. Methods: We conducted a cross-sectional study consisting of 1551 participants from the National Heart, Lung and Blood Institute Family Heart Study to assess the relation of Apo E polymorphism with the prevalence of MetS. MetS was defined according to the American Heart Association-National Heart, Lung and Blood Institute-International Diabetes Federation-World Health Organization harmonized criteria. We used generalized estimating equations to estimate adjusted odds ratios (ORs) for prevalent MetS and the Bonferroni correction to account for multiple testing in the secondary analysis. Results: Our study population had a mean age (standard deviation) of 56.5 (11.0) years, and 49.7% had MetS. There was no association between the Apo E genotypes and the MetS. The multivariable adjusted ORs (95% confidence interval) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62-1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the E{open}3/E{open}3, E{open}2/E{open}2, E{open}2/E{open}3, E{open}2/E{open}4, E{open}3/E{open}4 and E{open}4/E{open}4 genotypes, respectively. In a secondary analysis, E{open}2/E{open}3 genotype was associated with 41% lower prevalence odds of low high-density lipoprotein [multivariable adjusted ORs (95% confidence interval)=0.59 (0.36-0.95)] compared with E{open}3/E{open}3 genotype. Conclusions: Our findings do not support an association between Apo E polymorphism and MetS in a multicentre population-based study of predominantly White US men and women.

AB - Objective: Metabolic syndrome (MetS), characterized by abdominal obesity, atherogenic dyslipidaemia, elevated blood pressure and insulin resistance, is a major public health concern in the United States. The effects of apolipoprotein E (Apo E) polymorphism on MetS are not well established. Methods: We conducted a cross-sectional study consisting of 1551 participants from the National Heart, Lung and Blood Institute Family Heart Study to assess the relation of Apo E polymorphism with the prevalence of MetS. MetS was defined according to the American Heart Association-National Heart, Lung and Blood Institute-International Diabetes Federation-World Health Organization harmonized criteria. We used generalized estimating equations to estimate adjusted odds ratios (ORs) for prevalent MetS and the Bonferroni correction to account for multiple testing in the secondary analysis. Results: Our study population had a mean age (standard deviation) of 56.5 (11.0) years, and 49.7% had MetS. There was no association between the Apo E genotypes and the MetS. The multivariable adjusted ORs (95% confidence interval) were 1.00 (reference), 1.26 (0.31-5.21), 0.89 (0.62-1.29), 1.13 (0.61-2.10), 1.13 (0.88-1.47) and 1.87 (0.91-3.85) for the E{open}3/E{open}3, E{open}2/E{open}2, E{open}2/E{open}3, E{open}2/E{open}4, E{open}3/E{open}4 and E{open}4/E{open}4 genotypes, respectively. In a secondary analysis, E{open}2/E{open}3 genotype was associated with 41% lower prevalence odds of low high-density lipoprotein [multivariable adjusted ORs (95% confidence interval)=0.59 (0.36-0.95)] compared with E{open}3/E{open}3 genotype. Conclusions: Our findings do not support an association between Apo E polymorphism and MetS in a multicentre population-based study of predominantly White US men and women.

KW - Apolipoprotein E (Apo E) polymorphism

KW - Blood pressure

KW - Dyslipidaemia

KW - Glucose

KW - High-density lipoprotein cholesterol

KW - Metabolic syndrome

UR - http://www.scopus.com/inward/record.url?scp=84941260175&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84941260175&partnerID=8YFLogxK

U2 - 10.1002/dmrr.2638

DO - 10.1002/dmrr.2638

M3 - Article

C2 - 25656378

AN - SCOPUS:84941260175

VL - 31

SP - 582

EP - 587

JO - Diabetes/Metabolism Research and Reviews

JF - Diabetes/Metabolism Research and Reviews

SN - 1520-7552

IS - 6

ER -